NeuroOne Medical Technologies Corp (NMTC) 2025 Q1 法說會逐字稿

Good day, ladies and gentlemen. Welcome to the first quarter of fiscal year 2025 financial results conference call for NeuroOne Medical Technologies Corporation. Today's call will be conducted by the company's Chief Executive Officer, Dave Rosa, and Ron McClurg, the company's Chief Financial Officer. Chris Volker, the company's Chief Operating Officer, will also be in attendance.

女士們、先生們，大家好。歡迎參加 NeuroOne Medical Technologies Corporation 2025 財年第一季財務業績電話會議。今天的電話會議將由公司執行長戴夫·羅薩 (Dave Rosa) 和公司財務長 Ron McClurg 主持。該公司首席營運長克里斯沃爾克 (Chris Volker) 也將出席此次會議。

Before I turn the call over to Mr. Rosa, I'd like to remind you that this conference call will include forward-looking statements, within the meaning of US Federal Securities Laws with respect to future operations, financial results, events, trends, and performance, which are based on management's beliefs and assumptions as of today's call or other specified date.

在我將電話轉給羅薩先生之前，我想提醒您，本次電話會議將包括前瞻性陳述，這些陳述符合美國聯邦證券法對未來營運、財務結果、事件、趨勢和業績的定義，這些陳述基於管理層在今天電話會議或其他指定日期的信念和假設。

Forward-looking statements, including statements regarding our fiscal 2025 guidance, may involve known and unknown risks, uncertainties, and other factors, which may cause actual results to differ materially from those expressed or implied by such statements. See NeuroOne's financial results press release and SEC filings for information regarding specific risks and uncertainties that could cause actual results to differ. Except as required by law, NeuroOne undertakes no obligation to update such forward-looking statements.

前瞻性陳述，包括有關我們 2025 財年指引的陳述，可能涉及已知和未知的風險、不確定性和其他因素，這些因素可能導致實際結果與此類陳述表達或暗示的結果有重大差異。有關可能導致實際結果不同的特定風險和不確定性的信息，請參閱 NeuroOne 的財務業績新聞稿和 SEC 文件。除法律要求外，NeuroOne 不承擔更新此類前瞻性聲明的義務。

With that, I will turn the call over to Mr. Dave Rosa, CEO of NeuroOne. Please go ahead, sir.

說完這些，我會把電話轉給 NeuroOne 執行長戴夫·羅薩先生。先生，請繼續。

Thanks, operator. For those of you who may be new to NeuroOne, we are a medical technology company that is dedicated to transforming the diagnosis and treatment of neurological disorders. Initially with epilepsy, where we have minimally invasive, high-definition solutions for EEG recording, brain stimulation, and ablation solutions for patients.

謝謝，接線生。對於可能不熟悉 NeuroOne 的人來說，我們是一家致力於改變神經系統疾病診斷和治療的醫療科技公司。首先是癲癇，我們為患者提供微創、高畫質腦電圖記錄解決方案、腦部刺激和消融解決方案。

Our patented and disruptive OneRF Ablation System, the first and only FDA-cleared product that uses the same sEEG electrode for both diagnostic and therapeutic applications, is performing extremely well in treating patients suffering from seizures due to epilepsy. We hope to expand the number of patients willing to opt for this therapy, given it is designed to reduce the number of hospitalizations and procedures while improving outcomes.

我們獲得專利的、具有突破性的 OneRF 消融系統是第一個也是唯一一個獲得 FDA 批准的、使用相同 sEEG 電極進行診斷和治療應用的產品，在治療癲癇發作患者方面表現非常出色。我們希望增加願意選擇這種療法的患者數量，因為它旨在減少住院和手術次數，同時改善治療效果。

During our fiscal first quarter and through today, we have continued to execute our plan and have accomplished several key milestones regarding commercialization, product development, and financial objectives. I am very proud to report that we have achieved record product sales of $3.3 million as well as record product gross margins of 58.9% in the first quarter. This represents revenue growth of 235% when compared to revenue of $1 million in the first quarter of fiscal 2024. And almost double our product gross margins, which were 27% in the first quarter of fiscal 2024.

在我們的第一個財務季度直至今天，我們繼續執行我們的計劃，並在商業化、產品開發和財務目標方面完成了幾個關鍵的里程碑。我很自豪地報告，我們在第一季實現了創紀錄的 330 萬美元的產品銷售額以及創紀錄的 58.9% 的產品毛利率。與 2024 財年第一季的 100 萬美元營收相比，這意味著營收成長了 235%。我們的產品毛利率幾乎翻了一番，2024 財年第一季為 27%。

The strong financial performance is a result of the deepening partnership with Zimmer Biomet. As a reminder, our relationship with Zimmer Biomet began in 2020, and in October 2024, we announced the expansion of our partnership with Zimmer Biomet to include exclusive distribution rights for the OneRF Ablation System in the United States and certain outside US geographies.

強勁的財務表現是與 Zimmer Biomet 不斷深化的合作夥伴關係的結果。提醒一下，我們與 Zimmer Biomet 的關係始於 2020 年，2024 年 10 月，我們宣布擴大與 Zimmer Biomet 的合作夥伴關係，包括在美國和美國以外某些地區的 OneRF 消融系統的獨家分銷權。

In consideration for the expanded partnership, NeuroOne received an upfront license payment of $3 million and the potential to earn an additional milestone payment if certain performance criteria are achieved. Combined, we are reporting total first quarter revenue of $6.3 million, also a record for NeuroOne. The expanded partnership with Zimmer Biomet includes improved transfer prices and is expected to boost NeuroOne revenue and to drive improved profitability, given their extensive distribution network and scale.

考慮到擴大的合作夥伴關係，NeuroOne 獲得了 300 萬美元的預付許可費，並且如果達到某些績效標準，還可能獲得額外的里程碑付款。綜合來看，我們報告第一季總收入為 630 萬美元，這也創下了 NeuroOne 的最高紀錄。與 Zimmer Biomet 擴大的合作關係包括改善轉讓價格，並有望提高 NeuroOne 的收入，並提高盈利能力，因為其擁有廣泛的分銷網絡和規模。

Regarding the launch of the OneRF Ablation System, we completed the initial stocking orders to Zimmer Biomet during the first quarter. Zimmer Biomet is one of the largest global medical device companies in the United States and has a strong presence in the epilepsy market. There are approximately 200 level four epilepsy centers in the United States, and Zimmer's robotic system is used in the majority of the epilepsy procedures performed each year. For NeuroOne, we believe the relationship positions us for significant growth and provides a faster timeline to mass adoption.

關於OneRF消融系統的推出，我們在第一季完成了Zimmer Biomet的初始庫存訂單。Zimmer Biomet 是美國最大的全球醫療器材公司之一，在癲癇市場佔有重要地位。美國大約有 200 個四級癲癇中心，每年執行的大多數癲癇手術都使用 Zimmer 的機器人系統。對於 NeuroOne 而言，我們相信這種合作關係將為我們帶來顯著的成長，並能更快地實現大規模應用。

We are pleased to report that in all but one of the OneRF Ablation procedures performed to date, the patients are seizure free. However, that one patient has experienced a significant reduction in seizure occurrence and less severe seizures after the OneRF Ablation procedure was performed. We are especially happy to report that one of the patients has now been seizure-free for over nine months, following the OneRF Ablation procedure, enabling the patient to enjoy significant improvement in quality of life.

我們很高興地報告，迄今為止執行的所有 OneRF 消融手術中，除一項手術外，患者均沒有癲癇發作。然而，在進行 OneRF 消融手術後，該患者癲癇發作的次數明顯減少，且嚴重程度也減輕。我們特別高興地報告，其中一名患者在接受 OneRF 消融手術後，已經 9 個多月沒有再發作癲癇，生活品質顯著改善。

These exciting results confirm that this technology is a game changer. Instead of patients having to undergo two hospitalizations with multiple procedures that are typically a few months apart, with the OneRF Ablation System, they can now undergo one hospitalization that allows the neurosurgeon to use the same electrode for both diagnostic and ablation purposes.

這些令人興奮的結果證實，這項技術將改變遊戲規則。患者不再需要住院兩次並接受通常相隔數月的多項手術，而使用 OneRF 消融系統後，他們只需住院一次，神經外科醫生便可使用同一電極進行診斷和消融。

As noted, our OneRF Ablation System remains the first and only FDA-cleared RF ablation system for brain procedures using a single implant for both diagnostic and therapeutic applications, creating a unique competitive and a first mover advantage. Hospitals are increasingly favoring FDA-cleared solutions over off-label alternatives. Second, physicians are more inclined to use an approved system, reducing liability concerns. And lastly, patients are more trusting of approved technology.

如上所述，我們的 OneRF 消融系統仍然是第一個也是唯一一個獲得 FDA 批准的用於腦部手術的射頻消融系統，該系統使用單一植入物進行診斷和治療應用，創造了獨特的競爭優勢和先發優勢。醫院越來越青睞經 FDA 核准的解決方案，而非未列入藥品說明書的替代方案。其次，醫生更傾向於使用經過批准的系統，從而減少責任擔憂。最後，患者對經過認可的技術更加信任。

Also important to hospitals, the new ICD-10 PCS code granted by CMS for the OneRF Ablation procedure became effective October 1, 2024, which will allow hospitals to report inpatient procedures that are performed using the OneRF Ablation System. This will serve to support accurate data collection and processing of reimbursement claims by hospitals for the procedure.

對醫院來說同樣重要的是，CMS 為 OneRF 消融手術授予的新 ICD-10 PCS 代碼將於 2024 年 10 月 1 日生效，這將允許醫院報告使用 OneRF 消融系統執行的住院手術。這將有助於醫院準確收集數據並處理該程序的報銷索賠。

Leveraging our ablation system to treat pain in other areas of the body, we remain on track to submit a 510(k) application to the FDA in the first half of calendar year 2025 for our new Trigeminal Nerve RF Ablation System designed to treat patients with debilitating facial pain, also known as trigeminal neuralgia.

利用我們的消融系統治療身體其他部位的疼痛，我們仍有望在2025年上半年向FDA提交510（k）申請，用於我們的新型三叉神經射頻消融系統，用於治療患有使人衰弱的面部疼痛（也稱為三叉神經痛）的患者。

The trigeminal nerve is located in the face, with one nerve on each side of the face. Trigeminal neuralgia is a chronic pain condition and is characterized by severe, sudden, and recurrent facial pain, with over 150,000 patients diagnosed each year in the United States. NeuroOne's Trigeminal Nerve RF Ablation System has the potential to contribute to revenue in calendar year 2025, that is not currently factored in our 2025 revenue plan nor our revenue guidance.

三叉神經位於臉部，臉部左右兩側各有一條神經。三叉神經痛是一種慢性疼痛疾病，其特徵是嚴重、突然和復發的臉部疼痛，美國每年有超過 15 萬名患者被診斷出患有此病。NeuroOne 的三叉神經射頻消融系統有可能在 2025 日曆年帶來收入，但目前尚未計入我們的 2025 年收入計劃和收入指導中。

With regard to our other product development programs, leveraging our thin film electrode platform technology, we are continuing to make progress exploring potential strategic partnerships to further develop and commercialize our spinal cord stimulation and drug delivery technologies, both of which would benefit immensely from the multi-function capabilities that NeuroOne's technology can offer.

至於我們的其他產品開發計劃，利用我們的薄膜電極平台技術，我們正在繼續探索潛在的策略合作夥伴關係，以進一步開發和商業化我們的脊髓刺激和藥物輸送技術，這兩項技術都將極大地受益於 NeuroOne 技術所能提供的多功能能力。

Before I turn it over to Ron, I would also like to comment on a few financial updates. We are off to a great start with our financial results in the first quarter. And with this confidence, we are reiterating our fiscal year 2025 guidance. We expect product revenue to be in the range of $8 to $10 million, representing an increase of between 132% and 190% over 2024. And product gross margins to be between 47% and 51% compared to 31% in 2024. Importantly, this guidance excludes our upfront license payments received from Zimmer.

在將其交給羅恩之前，我還想對一些財務更新發表評論。我們第一季的財務表現開局良好。憑藉這種信心，我們重申 2025 財年的指導方針。我們預計產品收入將在 800 萬至 1,000 萬美元之間，比 2024 年成長 132% 至 190%。產品毛利率將從 2024 年的 31% 成長至 47% 至 51% 之間。重要的是，該指引不包括我們從 Zimmer 收到的預付許可費用。

Additionally, we have been able to strengthen our balance sheet in the first quarter with the $3 million license payment from Zimmer Biomet, along with the improved transfer prices from the expanded Zimmer, partnership driving improved product gross margins. Finally, I am also pleased to announce that we have regained compliance with Nasdaq share price listing standards and are grateful to all of our shareholders for their patience during this time.

此外，我們在第一季從 Zimmer Biomet 獲得了 300 萬美元的許可費，加上 Zimmer 擴張帶來的轉讓價格提高，合作夥伴關係推動了產品毛利率的提高，從而增強了我們的資產負債表。最後，我也很高興地宣布，我們已經重新符合納斯達克股價上市標準，並感謝所有股東在此期間的耐心等待。

I would now like to turn the call over to Ron McClurg to provide a review of our fiscal first quarter financial results. Ron.

現在，我想將電話轉給 Ron McClurg，讓他回顧一下我們第一財季的財務表現。羅恩。

Thanks, Dave. Product revenue was $3.3 million in the first quarter of fiscal 2025, an increase of 235% compared to our product revenue of $1 million in the first quarter of fiscal 2024. The company also had license revenue of $3 million in the first quarter of fiscal 2025 compared to no license revenue in the first quarter of fiscal '24. License revenue in the first quarter of fiscal '25 was derived from the expanded exclusive distribution agreement with Zimmer Biomet.

謝謝，戴夫。2025財年第一季的產品收入為330萬美元，與2024財年第一季的100萬美元產品收入相比成長了235％。該公司在 2025 財年第一季的授權收入為 300 萬美元，而 2024 財年第一季則沒有授權收入。25 財年第一季的授權收入來自與 Zimmer Biomet 擴大的獨家經銷協議。

Product gross profit increased significantly to $1.9 million or 58.9% of revenue in the first quarter of fiscal 2025 compared to product gross profit of $0.3 million or 27.2% of revenue in the first quarter of fiscal 2024. Total operating expenses in the first quarter of fiscal 2025 were $3.2 million, a decrease of 12% compared to $3.7 million in the first quarter of fiscal 2024.

2025 財年第一季的產品毛利大幅增加至 190 萬美元，佔營收的 58.9%，而 2024 財年第一季的產品毛利為 30 萬美元，佔營收的 27.2%。2025財年第一季的總營運費用為320萬美元，較2024財年第一季的370萬美元下降12%。

R&D expense in the first quarter of fiscal '25 decreased to $1.2 million compared to $1.5 million in the same period of fiscal 2024. SG&A expense in the first quarter of fiscal 2025 also decreased to $2.0 million compared to $2.2 million in the first quarter of fiscal 2024. For the first quarter of fiscal 2025, the company reported net income of $1.8 million or $0.06 per share compared to a net loss of $3.3 million or a loss of $0.14 per share in the first quarter of fiscal 2024.

2025 財年第一季的研發費用從 2024 財年同期的 150 萬美元下降至 120 萬美元。2025 財年第一季的銷售、一般及行政費用 (SG&A) 也從 2024 財年第一季的 220 萬美元下降至 200 萬美元。2025 財年第一季度，該公司報告淨收入為 180 萬美元，即每股虧損 0.06 美元，而 2024 財年第一季的淨虧損為 330 萬美元，即每股虧損 0.14 美元。

As of December 31, 2024, the company had cash and cash equivalents of $1.1 million compared to $1.5 million as of September 30, 2024. The company had working capital of $4.1 million as of December 31, 2024, compared to working capital of $2.4 million as of September 30, 2024. The company had no debt outstanding as of December 31, 2024.

截至 2024 年 12 月 31 日，該公司的現金和現金等價物為 110 萬美元，而截至 2024 年 9 月 30 日為 150 萬美元。截至 2024 年 12 月 31 日，該公司的營運資本為 410 萬美元，而截至 2024 年 9 月 30 日的營運資本為 240 萬美元。截至 2024 年 12 月 31 日，該公司沒有未償還債務。

Following receipt of the $3 million dollar license payment from Zimmer Biomet in November of 2024, the company terminated the $3 million standby secured credit facility agreement.

在 2024 年 11 月收到 Zimmer Biomet 支付的 300 萬美元許可費後，該公司終止了 300 萬美元的備用擔保信貸協議。

For the full fiscal year 2025 financial guidance, given that we recently completed the initial stocking order to Zimmer in December, we expect product revenue will decline sequentially in the second quarter of fiscal 2025, and then ramp through the end of the fiscal year as the product launch expands.

對於 2025 財年全年財務指引，鑑於我們最近在 12 月完成了對 Zimmer 的初始庫存訂單，我們預計產品收入將在 2025 財年第二季度環比下降，然後隨著產品發布的擴大，在財年末之前逐漸上升。

As Dave mentioned, the company is reiterating fiscal year 2025 guidance and expects product revenue for fiscal year 2025 to range between $8 million and $10 million, representing an increase of between 132% and 190% when compared to product revenue of $3.5 million in fiscal year 2024. The company also expects product gross margin in the full fiscal year 2025 to range between 47% and 51% compared to product gross margin of 31% in fiscal 2024.

正如戴夫所說，該公司重申了 2025 財年的指導方針，並預計 2025 財年的產品收入將在 800 萬美元至 1000 萬美元之間，與 2024 財年的 350 萬美元的產品收入相比增長 132% 至 190%。該公司還預計 2025 財年全年產品毛利率將在 47% 至 51% 之間，而 2024 財年的產品毛利率為 31%。

Operator, at this time, I think we can open up for questions.

接線員，現在我想我們可以開始提問了。

(Operator Instructions)

（操作員指令）

Hi, everyone, and congratulations on a great quarter. I'd like to just ask a few questions that were submitted. Dave, maybe first off, why have your results been so positive to date and what is the measuring stick for clinical success for epilepsy?

大家好，恭喜您度過了一個美好的季度。我只想問幾個已經提交的問題。戴夫，首先，為什麼到目前為止你的結果如此積極，以及衡量癲癇臨床成功的標準是什麼？

Sure. So it's been a preferred therapy for patients that have epilepsy to actually use ablation technology, whether it's radio frequency ablation or laser ablation. For those patients that are resistant to pharmacologic therapy, it's been the preferred method. So, I'm not surprised that we're having success. But the success we're having, I think, part of the reason is that we're using the same device to both do the diagnostic procedure as well as the therapeutic.

當然。因此，對於患有癲癇的患者來說，使用消融技術一直是首選的治療方法，無論是射頻消融還是雷射消融。對於那些對藥物治療有抗藥性的患者，這是首選方法。因此，我對我們的成功並不感到驚訝。但我認為，我們成功的部分原因是我們使用同一設備進行診斷程序和治療。

So, typically within a week, the diagnostic process is able to determine precisely the tissue that's triggering the seizures. And given the fact that we're not sending the patient home and replacing the device when they come back a few months later, we're doing this really all in one hospitalization. I think it certainly contributes to the success that we're having.

因此，通常在一週內，診斷過程就能夠準確地確定引發癲癇的組織。考慮到我們不會讓患者回家，等他們幾個月後再回來更換設備，我們實際上是在一次住院治療中完成這一切。我認為這確實對我們的成功有所貢獻。

The measuring stick for epilepsy patients, typically what you'll see in the clinical literature is that it's the timeline is either one year post-surgery seizure-free or dramatically improved reduction in seizures. So, as we mentioned in the discussion, right now, the patient that's been treated the longest is a bit beyond nine months. So it'll be interesting to see over the course of the next 12 months, how many of those patients remain seizure-free or are dramatically improved. But we're off to a great start with that.

癲癇患者的衡量標準，通常您會在臨床文獻中看到的是，其時間表是手術後一年內無癲癇發作或癲癇發作顯著減少。因此，正如我們在討論中所提到的，目前，接受治療時間最長的患者已超過九個月。因此，觀察未來 12 個月內有多少患者能夠繼續保持無癲癇發作狀態或病情顯著好轉將會十分有趣。但我們在這方面已經有了很好的開始。

Great. Thank you. And the second one is, you reported a really strong product gross margin of almost 60% in Q1, and your guidance for the year is expected to range between 47% and 51%. Do you think these levels of margin are sustainable long term?

偉大的。謝謝。第二個問題是，你們報告第一季產品毛利率非常強勁，接近 60%，預計全年毛利率將在 47% 至 51% 之間。您認為這些利潤水準能夠長期維持嗎？

I'm very confident that the margins of 47% to 51% are sustainable. The reason why we saw a higher gross margin in Q1 was, if you remember, prior to finalizing the agreement, the extension with Zimmer Biomet, NeuroOne was actually commercializing the technology directly, and because of that our margins were higher. But we're very confident and really expect those margins to be within the range that we provided in guidance, and that's 47% to 51%.

我非常有信心 47% 至 51% 的利潤率是可持續的。如果你還記得的話，我們在第一季看到更高的毛利率的原因是，在最終達成協議之前，與 Zimmer Biomet 的延期，NeuroOne 實際上是直接將該技術商業化，因此我們的利潤率更高。但我們非常有信心，並真正預計這些利潤率將在我們指導的範圍內，即 47% 到 51%。

Thank you. And the final question is, what does NeuroOne have to do before submitting the 510(k) application for facial pain? And as a follow up, how long is the expected FDA review for that?

謝謝。最後一個問題是，NeuroOne 在提交臉部疼痛治療 510(k) 申請之前要做什麼？另外，FDA 預計審查需要多久？

It's always a tough question to determine how long it's going to take to get through FDA clearance, but the good news here is that we said we expect to submit it in the first half of calendar 2025, and we're certainly still on track with that. There is some remaining testing that we have to perform, things like sterilization testing, packaging, that's really required to be included in the FDA submission. But the good news here is that we've actually already kicked off the process of putting the application together for the submission.

確定通過 FDA 批准需要多長時間始終是一個難題，但好消息是，我們表示預計將在 2025 年上半年提交該申請，而且我們肯定仍在按計劃進行。我們還需要進行一些剩餘的測試，例如滅菌測試、包裝，這些確實需要包含在 FDA 提交中。但好消息是，我們實際上已經開始了申請提交的流程。

And in terms of the expected FDA review and the timing of that, I guess what I would say is our last mission, which was for the OneRF Ablation System in the brain, that took about five months from the time we submitted to the time that we actually received clearance. So assuming we stay on track and we submit this by mid-year, I would expect that it would probably be somewhere in that range of what we've experienced before. But it's not a guarantee. But we've had great success, especially, with our ablation system for use in the brain.

關於預期的 FDA 審查及其時間安排，我想說的是，我們的最後一個任務是針對大腦的 OneRF 消融系統，從我們提交申請到實際獲得批准大約花了五個月的時間。因此，假設我們保持進度並在年中之前提交這份報告，我預計它可能會處於我們之前所經歷的範圍內。但這並不能保證。但我們已經取得了巨大的成功，尤其是用於大腦的消融系統。

Excellent. Congrats on a great quarter.

出色的。恭喜您度過了一個美好的季度。

Thank you.

謝謝。

Thank you. We have reached the end of the question-and-answer session, and I would now like to turn a call back to Dave for closing remarks.

謝謝。問答環節已經結束，現在我想請戴夫作結語。

Thank you, operator. In summary, this was a transformational quarter for NeuroOne. We delivered record revenue, implemented and executed on our strategic partnership with Zimmer Biomet, and continued building momentum in the market. With our first mover advantage, growing clinical adoption, and strong commercial execution, we are well positioned for significant full fiscal year 2025 growth.

謝謝您，接線生。總而言之，對於 NeuroOne 來說，這是一個轉型季度。我們實現了創紀錄的收入，實施並執行了與 Zimmer Biomet 的戰略合作夥伴關係，並繼續在市場上保持強勁勢頭。憑藉我們的先發優勢、不斷增長的臨床應用以及強大的商業執行力，我們已為 2025 財年全年實現顯著增長做好了準備。

We are happy to reiterate our guidance for both product revenue and product gross margin for the full fiscal year 2025 as mentioned during the session. The potential to commercialize our Trigeminal Nerve RF Ablation System in late calendar year 2025 represents our next growth driver, and we are continuing to make progress on longer term product development programs, leveraging our platform technology.

我們很高興重申會議期間提到的 2025 財年全年產品收入和產品毛利率的指引。我們的三叉神經射頻消融系統預計將在 2025 年底實現商業化，這代表著我們的下一個成長動力，我們將利用我們的平台技術，繼續在長期產品開發計畫方面取得進展。

I would like to again thank everyone for attending the call, and we look forward to connecting with the investor community throughout the next quarter.

我要再次感謝大家參加電話會議，我們期待在下個季度與投資者社群建立聯繫。

Thank you. This does conclude today's conference. We thank you for your participation. You may disconnect your lines at this time and have a wonderful day.

謝謝。今天的會議到此結束。我們感謝您的參與。此時您可以斷開您的線路並享受美好的一天。